Answers are grounded in this paper and cite their sources.
Research demonstrates improved risk evaluation and diagnosis of acute coronary syndrome through biomarker-driven multiomics strategies, indicating potential for personalized therapy.
With rapid advancements in genomics, proteomics, and metabolomics researchers have gained significant insights into ACS (ACS) pathogenesis. Studies have revealed specific biomarkers linked to ACS and provided novel tools for risk evaluation and early diagnosis. Genomic breakthroughs have enabled exploration of genetic factors contributing to ACS. Transcriptomics has facilitated the analysis of gene expression alterations in patients with ACS. Proteomics has identified potential therapeutic targets by pinpointing biomarkers, paving the way for new drug development. Advances in metabolomics have enabled monitoring of changes in metabolic pathways, offering valuable information for early diagnosis and disease prognosis. In summary, multiomics research has shed light on the critical aspects of ACS clinical strategies, facilitating advancements in early diagnosis, risk assessment, and personalized therapy, and will increasingly assume a pivotal role in future clinical practice.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: